Autoimmune peripheral neuropathies

Clinical Immunology

Volumn , Issue , 2008, Pages 977-994

  Dalakas, Marinos C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882888966     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-323-04404-2.10066-1     Document Type: Chapter

References (48)

1. Asbury A.K., Arnason B.G., Adams R.D. The inflammatory lesion in idiopathic polyneuritis: its role in pathogenesis. Medicine (Baltimore) 1969, 48:173-215.
2. Hughes R.A., Cornblath D.R. Guillain-Barré syndrome. Lancet 2005, 366:1653-1666.
3. Feasby T.E., Hahn A.F., Brown W.F., et al. Severe axonal degeneration in acute Guillain-Barré syndrome: evidence of two different mechanisms?. J Neurol Sci 1993, 116:185-192.
4. Feldman E.L., Bromberg M.B., Blaivas M., Junck L. Acute pandysautonomic neuropathy. Neurology 1991, 41:746-748.
5. LaRocca R.V., Meer J., Gilliatt R., et al. Suramin-induced polyneuropathy. Neurology 1990, 40:954-960.
6. Ilyas A.A., Mithen F.A., Chen Z.W., Cook S.D. Search for antibodies to neutral glycolipids in sera of patients with Guillain-Barré syndrome. J Neurol Sci 1991, 102:67-75.
7. Willison H.J., Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002, 125:2591-2625.
8. Chiba A., Kusunoki S., Obata H. Serum anti GQ1b IgG antibody is associated with ophthalmoplegia in Miller-Fisher syndrome and Guillain-Barré syndrome. Neurology 1993, 43:1911-1917.
9. Yuki N., Susuki K., Koga M., et al. Carbohydrate mimicry between human ganglioside GM1 and Campylobacter jejuni lipooligosaccharide causes Guillain-Barré syndrome. Proc Natl Acad Sci USA 2004, 101:11404-11409.
10. Illa I., Ortiz N., Gallard E., et al. Acute axonal Guillain-Barré syndrome with IgG antibodies against motor axons following parenteral gangliosides. Ann Neurol 1995, 38:218-224.
11. Ang C.W., Jacobs B.C., Laman J.D. The Guillain-Barré syndrome: a true case of molecular mimicry. Trends Immunol 2004, 25:61-66.
12. Koller H., Kieseier B.C., Jander S., Hartung H.P. Chronic inflammatory demyelinating polyneuropathy. N Engl J Med 2005, 352:1343-1356.
13. Dalakas M.C., Engel W.K. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol 1981, 10:134-145.
14. Dalakas M.C. Advances in chronic inflammatory demyelinating polyneuropathy: disease variants and inflammatory response mediators and modifiers. Curr Opin Neurol 1999, 12:403-409.
15. Murata K., Dalakas M.C. Expression of the co-stimulatory molecule BB-1, the ligands CTLA-4 and CD28 and their mRNAs in chronic inflammatory demyelinating polyneuropathy. Brain 2000, 123:1660-1666.
16. Dalakas M., Engel W.K. Immunoglobulin deposits in chronic relapsing polyneuropathies. Arch Neurol 1980, 37:637-640.
17. Weiss M.D., Luciano C.A., Semino-Mora C., et al. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 1998, 51:1738-1741.
18. Dalakas M.C., Engel W.K. Polyneuropathy and monoclonal gammopathy: studies of 11 patients. Ann Neurol 1981, 10:45-52.
19. Latov N., Braun P.E., Gross R.B., et al. Plasma cell dyscrasia and peripheral neuropathy: identification of the myelin antigens that react with human paraproteins. Proc Natl Acad Sci USA 1981, 78:7139.
20. Kelly J.J., Kyle R.A., O'Brien P.C., Dyck P.J. The prevalence of monoclonal gammopathy in peripheral neuropathy. Neurology 1981, 31:1480-1483.
21. Latov N., Hays A., Sherman W.H. Peripheral neuropathy and anti-MAG antibodies. Crit Rev Neurobiol 1988, 3:301-332.
22. Kyle R.A., Therneau T.M., Rajkumar S.V., et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006, 354:1362-1369.
23. Dispenzieri A., Kyle R.A., Lacy M.Q., et al. POEMS syndrome: definitions and long-term outcome. Blood 2003, 101:2496-2506.
24. Nakanishi T., Sobue I., Toyokura Y., et al. The Crow-Fukase syndrome: a study of 102 cases in Japan. Neurology 1984, 34:712-720.
25. Dalakas M.C. Chronic idiopathic ataxic neuropathy. Ann Neurol 1986, 19:545-554.
26. Mendell J.R., Sahenk Z., Whitaker J.N., et al. Polyneuropathy and monoclonal gammopathy: studies on the pathogenetic role of anti-myelin-associated glycoprotein antibody. Ann Neurol 1985, 17:243-254.
27. Ilyas A.A., Quarles R.H., McIntosh T.D., et al. IgM in a human neuropathy related to paraproteinemia binds to a carbohydrate determinant in the myelin-associated glycoprotein and to a ganglioside. Proc Natl Acad Sci USA 1984, 81:1225-1229.
28. Ilyas A.A., Quarles R.H., Dalakas M.C., Brady R.O. Polyneuropathy with monoclonal gammopathy: glycolipids are frequently antigens for IgM paraproteins. Proc Natl Acad Sci USA 1985, 82:6697-6700.
29. 4Gal NaC GD1a as antigens for monoclonal immunoglobulin M neuropathy associated with gammopathy. J Biol Chem 1988, 263:4369-4373.
30. Duane G.C., Farrer R.G., Dalakas M.C., Quarles R.H. Sensory neuropathy associated with monoclonal IgM to GD1b ganglioside. Ann Neurol 1992, 31:683-685.
31. Monaco S., Bonetti B., Ferrari S., et al. Complement dependent demyelination in patients with IgM monoclonal gammopathy and polyneuropathy. N Engl J Med 1990, 322:844-852.
32. Lombardi R., Erne B., Lauria G., et al. IgM deposits on skin nerves in anti-myelin-associated glycoprotein neuropathy. Ann Neurol 2005, 57:180-187.
33. Willison H.J., Trapp B.D., Bacher J.D., et al. Demyelination induced by intraneural injection of human antimyelin associated glycoprotein antibodies. Muscle Nerve 1988, 11:1169-1176.
34. Tatum A.H. Experimental paraprotein neuropathy; demyelination by passive transfer of human IgM anti-MAG. Ann Neurol 1993, 33:502-506.
35. Van Asseldonk J.T., Franssen H., Van den Berg-Vos R.M., et al. Multifocal motor neuropathy. Lancet Neurol 2005, 4:309-319.
36. Darnell R.B., Posner J.B. Paraneoplastic syndromes affecting the nervous system. Oncology 2006, 33:270-298.
37. Vernino S., Low P.A., Fealey R.D., et al. Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. N Engl J Med 2000, 343:847-855.
38. Lennon V.A., Ermilov L.G., Szurszewski J.H., Vernino S. Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. J Clin Invest 2003, 111:907-913.
39. Chalk C.H., Dyck P.J., Conn D.L. Vasculitic neuropathy. Peripheral neuropathy 1993, 1424-1436. WB Saunders, Philadelphia. P.J. Dyck, P.K. Thomas, J.W. Griffin (Eds.).
40. Dalakas M.C., Pezeshkpour G.H. Neuromuscular diseases associated with human immunodeficiency virus infection. Ann Neurol 1988, 23:38-48.
41. Dalakas M.C. Peripheral neuropathy and antiretroviral drugs. J Periph Nerv Syst 2001, 6:14-20.
42. McKhann G.M., Griffin J.W., Cornblath D.R. The Guillain-Barré Syndrome Study Group. Plasmapheresis and Guillain-Barré syndrome: analysis of prognostic factors and the effect of plasmapheresis. Ann Neurol 1988, 23:347-353.
43. Van der Meche F.G.A., Schmitz P.I.M. The Dutch Guillain-Barré syndrome. N Engl J Med 1992, 326:1123-1129.
44. Van Koningsveld R., Schmitz P.I.M., van der Meché F.G.A., et al. Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barré syndrome: randomised trial. Lancet 2004, 363:192-196.
45. Hahn A.F., Bolton C.F., Zochodne D., Feasby T.E. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy. A double-blind, placebo-controlled, cross-over study. Brain 1996, 119:1067-1077.
46. Hahn A.F., Bolton C.F., Pillay N., et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy. A double-blind, sham-controlled, cross-over study. Brain 1996, 119:1055-1066.
47. Dalakas M.C., Quarles R.H., Farrer R.G., et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 1996, 40:792-795.
48. Pestronk A., Florence J., Miller T., et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003, 74:485-489.